1
61
| Cat. No. | Product Name | ||
|---|---|---|---|
| CL0056 | CDK inhibitor kit | ||
| CL0137 | E1/E2/E3 Enzyme inhibitor kit | ||
| CL0136 | ATM/ATR inhibitor kit | ||
| L1610 | FDA 上市激酶抑制剂库 | 280 compounds | |
| Targetmol’s FDA-Approved Kinase Inhibitor Library contains 280 marketed drugs with proven kinase inhibitory activity. These kinases include Insulin/IGF Receptors、PI 3-Kinase、CaM Kinase II、JAK、PKA、CDK、JNK、PKC、CKI II、MAPK、RAF、EGFR、MEK、SAPK、GSK、MLCK、Src-family、IKK、PDGFR、VEGFR etc. FDA-Approved Kinase Inhibitor Library is a powerful tool for kinase drug development and related research. | |||
| CL0067 | Sodium Channel inhibitor kit | ||
| L1600 | 激酶抑制剂库 | 2230 compounds | |
| A unique collection of 2230 kinase inhibitors for high throughput screening and high content screening for drug discovery in kinase related diseases; | |||
| L3400 | 临床期小分子药物库 | 3142 compounds | |
| A unique collection of 3142 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS); | |||
| L6900 | 稀有天然产物库 | 284 compounds | |
| A unique collection of 284 rare natural products, which can be used for high throughput screening (HTS) and high content screening (HCS); | |||
| L2191 | 抗乳腺癌化合物库 | 1965 compounds | |
| A unique collection of 1965 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study； | |||
| L8100 | 细胞周期化合物库 | 695 compounds | |
| A unique collection of 695 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS); | |||
| NY1000 | 天然产物衍生物库 | 4000 compounds | |
| The library consists of more than 4,000 members belonging 22 scaffolds (average 180 compounds per scaffold). | |||
| L9411 | 半胱氨酸共价化合物库 | 72 compounds | |
| The cysteine covalent library contains 72 compounds. | |||
| DC1170 | 特权片段注释化合物库-Oxidoreductases | ||
| DC1150 | 特权片段注释化合物库-GPCR Family B | ||
| DC1100 | 特权片段注释化合物库-GPCR Frizzled family | ||
| DC1030 | 特权片段注释化合物库-Epigenetics | ||
| DC1200 | 特权片段注释化合物库-Isomerases | ||
| DC1040 | 特权片段注释化合物库-Transferases | ||
| DC1140 | 特权片段注释化合物库-Ligand-gated | ||
| DC1190 | 特权片段注释化合物库-Sigma Opioid receptors | ||
| DC1180 | 特权片段注释化合物库-Lyases | ||
| DC1050 | 特权片段注释化合物库-Voltage-gated | ||
| DC1010 | 特权片段注释化合物库-GPCR Family A | ||
| DC1160 | 特权片段注释化合物库-Toll-like and Il-1 receptors | ||
| DC1060 | 特权片段注释化合物库-Kinases | ||
| DC1220 | 特权片段注释化合物库-Aminoacyltransferases | ||
| DC1000 | 特权片段注释化合物库 | ||
| DC1110 | 特权片段注释化合物库-Proteases | ||
| DC1210 | 特权片段注释化合物库-Phosphatases | ||
| CL0103 | mGluR agonist/antagonist/modulator kit | ||
| DC1130 | 特权片段注释化合物库-Phosphodiesterases | ||
| DC1090 | 特权片段注释化合物库-Ligases | ||
| DC1230 | 特权片段注释化合物库-Beta amyloid A4 protein | ||
| DC1020 | 特权片段注释化合物库-Spiro Library | ||
| DC1080 | 特权片段注释化合物库-GPCR Taste family | ||
| DC1070 | 特权片段注释化合物库-GPCR Family C | ||
| DC1120 | 特权片段注释化合物库-Thrombopoietin receptors | ||
| CL0102 | Akt inhibitor/activator kit | ||
| DQ3000 | Factor XIa化合物库 | ||
| CL0139 | ROS inhibitor kit | ||
| CL0068 | VEGFR inhibitor kit | ||
| CL0126 | Androgen Receptor antagonist kit | ||
| L6020 | 天然产物单体化合物库 | ||
| CL0132 | DHFR inhibitor kit | ||
| CL0061 | Histone Methyltransferase inhibitor kit | ||
| L6700 | 抗癌天然产物库 | 1800 compounds | |
| A unique collection of 1800 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); | |||
| CL0059 | Dopamine Receptor inhibitor kit | ||
| L1380 | 转录因子库 | 704 compounds | |
| Well-chosen 704 compounds with unique structures targeting transcription factor; | |||
| L8400 | 血液病分子库 | 524 compounds | |
| A unique collection of 524 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS); | |||
| DF4600 | 类药性天然产物库 | ||
| L6400 | 海洋天然产物库 | 94 compounds | |
| A unique collection of 94 marine natural products for high throughput screening (HTS) and high content screening (HCS); | |||
| L1580 | GPCR库Plus | 338 compounds | |
| Well-chosen 338 GPCR targeting compounds with unique structures; | |||
| L2196 | 抗卵巢癌化合物库 | 1888 compounds | |
| L1500 | GPCR靶点分子库 | 1633 compounds | |
| A unique collection of 1633 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research; | |||
| L9830 | 抗帕金森病化合物库 | 908 compounds | |
| A unique collection of 908 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS. | |||
| VM1400 | 多样性核心库Part2 | ||
| DF4500 | 多样性核心库Part1 | ||
| L2190 | 抗肺癌化合物库 | 1735 compounds | |
| A unique collection of 1735 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study； | |||
| L6030 | 天然产物衍生物虚筛化合物库 | ||
| L9410 | 共价抑制剂库 | 941 compounds | |
| A unique collection of 941 covalent Inhibitors and other molecules with common warheads like chloroacetyl，2-Chloropropionyl，Acryloyl，sulfonyl fluoride, alkyne，acrylamide, ketocarbonyl，disulfide bond, etc. | |||
| CL0092 | GSK-3 inhibitor kit | ||
| Cat. No. | Product Name | Target | Signaling Pathways |
|---|---|---|---|
| T14919 | CDKI-73 | CDK; Apoptosis | Apoptosis; Cell Cycle/Checkpoint |
| CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin. | |||
沪公网安备 31010602006700号
